blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3148963

EP3148963 - 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS [Right-click to bookmark this link]
Former [2017/14]1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS
[2018/01]
StatusNo opposition filed within time limit
Status updated on  19.04.2019
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  11.05.2018
FormerGrant of patent is intended
Status updated on  21.12.2017
FormerRequest for examination was made
Status updated on  03.03.2017
FormerThe international publication has been made
Status updated on  25.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
GlaxoSmithKline Intellectual Property Development Limited
980 Great West Road
Brentford
Middlesex TW8 9GS / GB
[2017/14]
Inventor(s)01 / CHEN, Weichun
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shanghai 201203 / US
02 / IGBOKO, Ebere F
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shangha 201203 / US
03 / LIN, Xichen
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shanghai 201203 / US
04 / LU, Hongfu
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shangha 201203 / CN
05 / REN, Feng
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shangha 201203 / CN
06 / WREN, Paul Bryan
GlaxoSmithKline
1-3 Iron Bridge Road
Stockley Park West
Uxbridge Middlesex UB11 1BT / GB
07 / XU, Zhongmiao
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shangha 201203 / CN
08 / YANG, Ting
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shangha 201203 / CN
09 / ZHU, Lingdong
GlaxoSmithKline
Building 3
898 Halei Road
Zhangjiang Hi-Tech Park, Pudong
Shangha 201203 / CN
 [2017/14]
Representative(s)Knight, Lucie Viktoria, et al
GSK
Legal & Compliance - Global Patents
79 New Oxford Street
London WC1A 1DG / GB
[N/P]
Former [2017/14]Sewell, Richard Charles
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Application number, filing date15726090.227.05.2015
[2017/14]
WO2015EP61618
Priority number, dateWO2014CN0054529.05.2014         Original published format: PCT/CN2014/000545
WO2014CN8338031.07.2014         Original published format: PCT/CN2014/083380
WO2015CN7794730.04.2015         Original published format: PCT/CN2015/077947
[2017/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015181186
Date:03.12.2015
Language:EN
[2015/48]
Type: A1 Application with search report 
No.:EP3148963
Date:05.04.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 03.12.2015 takes the place of the publication of the European patent application.
[2017/14]
Type: B1 Patent specification 
No.:EP3148963
Date:13.06.2018
Language:EN
[2018/24]
Search report(s)International search report - published on:EP03.12.2015
ClassificationIPC:C07C211/56, C07D207/10, C07D211/54, C07D213/34, C07D233/64, C07D239/26, C07C275/30, C07D295/135, C07D305/06, C07D307/18, C07D309/08, C07D471/04, C07D487/04, A61K31/17, A61P11/00, A61P29/00
[2017/14]
CPC:
C07D307/18 (EP,CN,KR,US); C07C317/42 (EP,CN,KR,US); C07D213/34 (EP,CN,KR,US);
A61K31/17 (KR); A61P11/00 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P43/00 (EP);
C07C211/56 (CN); C07C275/30 (CN); C07C309/52 (CN);
C07C311/47 (EP,CN,US); C07C317/50 (EP,CN,KR,US); C07D207/04 (CN);
C07D207/10 (EP,CN,US); C07D211/54 (EP,CN,KR,US); C07D233/64 (EP,CN,KR,US);
C07D239/26 (EP,CN,KR,US); C07D241/04 (EP,US); C07D295/135 (EP,CN,KR,US);
C07D305/06 (EP,CN,KR,US); C07D307/08 (CN); C07D309/08 (EP,CN,KR,US);
C07D471/04 (EP,CN,US); C07D487/04 (EP,CN,US); C07C2601/04 (EP,US);
C07C2601/08 (EP,US); C07C2601/10 (EP,US); C07C2601/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/14]
Extension statesBA24.11.2016
ME24.11.2016
Validation statesMANot yet paid
TitleGerman:1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)HARNSTOFF-DERIVATE ALS CXCR2 INHIBITOREN[2018/01]
English:1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS[2018/01]
French:DERIVÉS D'URÉE 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL) EN TANT QU'INHIBITEURS DE CXCR2[2018/01]
Former [2017/14]1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)HARNSTOFF-DERIVATE ALS CXCR2-INHIBITOREN
Former [2017/14]1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS
Former [2017/14]DÉRIVÉS DE 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHÉNYL)-URÉE UTILISÉS COMME INHIBITEURS DE CXCR2
Entry into regional phase24.11.2016National basic fee paid 
24.11.2016Designation fee(s) paid 
24.11.2016Examination fee paid 
Examination procedure24.11.2016Amendment by applicant (claims and/or description)
24.11.2016Examination requested  [2017/14]
24.11.2016Date on which the examining division has become responsible
22.12.2017Communication of intention to grant the patent
17.04.2018Fee for grant paid
17.04.2018Fee for publishing/printing paid
17.04.2018Receipt of the translation of the claim(s)
Opposition(s)14.03.2019No opposition filed within time limit [2019/21]
Fees paidRenewal fee
08.05.2017Renewal fee patent year 03
07.05.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.05.2015
AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
MK13.06.2018
MT13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
[2022/31]
Former [2021/34]HU27.05.2015
AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
MT13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
Former [2021/32]HU27.05.2015
AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
Former [2020/29]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
PT15.10.2018
Former [2020/16]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
TR13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2020/07]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/51]AL13.06.2018
AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/26]AT13.06.2018
CY13.06.2018
CZ13.06.2018
DK13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SI13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/11]AT13.06.2018
CY13.06.2018
CZ13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SK13.06.2018
SM13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/10]AT13.06.2018
CY13.06.2018
CZ13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
PL13.06.2018
RO13.06.2018
RS13.06.2018
SE13.06.2018
SK13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/09]CY13.06.2018
EE13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/08]CY13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
IS13.10.2018
Former [2019/03]CY13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
NL13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
Former [2018/52]CY13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
GR14.09.2018
Former [2018/51]CY13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
Former [2018/50]CY13.06.2018
FI13.06.2018
HR13.06.2018
LT13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
Former [2018/49]CY13.06.2018
FI13.06.2018
LT13.06.2018
SE13.06.2018
BG13.09.2018
NO13.09.2018
Former [2018/47]FI13.06.2018
LT13.06.2018
NO13.09.2018
Cited inInternational search[A] WO0168084  (SMITHKLINE BEECHAM CORP et al.) [A] 1-17 * the whole document *
 [A] WO2007124424  (SMITHKLINE BEECHAM CORP et al.) [A] 1-17 * claims 1, 19-25 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.